{"generic":"Pegvisomant","drugs":["Pegvisomant","Somavert"],"mono":{"0":{"id":"jvu4s0","title":"Generic Names","mono":"Pegvisomant"},"1":{"id":"jvu4s1","title":"Dosing and Indications","sub":[{"id":"jvu4s1b4","title":"Adult Dosing","mono":"<ul><li><b>Acromegaly, Second-line therapy:<\/b> loading dose, 40 mg SUBQ once; administer under physician supervision<\/li><li><b>Acromegaly, Second-line therapy:<\/b> maintenance, 10 mg SUBQ once daily; adjust dose in 5-mg increments based on serum insulin-like growth factor (IGF-I) levels; MAX dose is 30 mg\/day<\/li><\/ul>"},{"id":"jvu4s1b5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in children "},{"id":"jvu4s1b6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic impairment (baseline):<\/b> liver function tests greater than 3 times the upper limit of normal, do not begin therapy until a comprehensive workup determines the cause of liver dysfunction<\/li><li><b>hepatic impairment (during therapy):<\/b> liver function tests greater than or equal to 3 times the upper limit of normal (ULN) but less than 5 times the ULN, continue therapy but perform a comprehensive workup to determine the cause of liver dysfunction<\/li><li><b>hepatic impairment (during therapy):<\/b> liver function tests (LFT) at least 5 times the upper limit of normal (ULN) or AST\/ALT at least 3 times the ULN with any increase in serum total bilirubin, discontinue therapy and perform a comprehensive workup (eg, serial LFT) to determine the cause of liver dysfunction; if LFT normalize, may restart therapy<\/li><li><b>hepatic impairment (during therapy):<\/b> signs and symptoms of hepatitis or other liver injury (eg, jaundice, bilirubinuria, right upper quadrant pain), perform a comprehensive workup and discontinue therapy if liver injury is confirmed<\/li><\/ul>"},{"id":"jvu4s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Acromegaly, Second-line therapy<br\/>"}]},"3":{"id":"jvu4s3","title":"Contraindications\/Warnings","sub":[{"id":"jvu4s3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jvu4s3b10","title":"Precautions","mono":"<ul><li>concomitant use with a somatostatin analogue (octreotide acetate) (unapproved use); increased risk of marked hepatic enzyme elevations (greater than 10 times the ULN)<\/li><li>cross-reactivity with growth hormone assays may occur<\/li><li>diabetes mellitus; glucose tolerance may improve; monitoring recommended<\/li><li>functional growth hormone deficiency may occur; monitoring recommended<\/li><li>growth hormone-secreting tumors; may expand during treatment; monitoring recommended<\/li><li>hypersensitivity reactions, systemic, have been reported (eg, anaphylactic\/anaphylactoid reactions, laryngospasm, angioedema); some patients required hospitalization; monitoring recommended if re-initiating therapy in patients with systemic hypersensitivity reaction<\/li><li>lipohypertrophy has been reported; rotate injection sites daily<\/li><li>liver enzyme elevations have been reported; monitoring recommended; therapy interruption or discontinuation may be necessary<\/li><li>liver test baseline levels greater than 3 times ULN; use not recommended until cause is identified; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jvu4s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jvu4s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jvu4s4","title":"Drug Interactions","sub":{"2":{"id":"jvu4s4b15","title":"Moderate","mono":"<ul>Octreotide (established)<\/ul>"}}},"5":{"id":"jvu4s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (4% to 11%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (0% to 14%), Nausea (0% to 14%)<\/li><li><b>Other:<\/b>Infectious disease (Infection, 0% to 23%), Influenza-like illness (4% to 12%), Pain (4% to 14%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hepatic:<\/b>Liver function tests abnormal (4% to 12%; greater than 10 to 15 times ULN, 0.8% to 2%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Other:<\/b>Anaphylactoid reaction<\/li><\/ul>"},"6":{"id":"jvu4s6","title":"Drug Name Info","sub":{"0":{"id":"jvu4s6b17","title":"US Trade Names","mono":"Somavert<br\/>"},"2":{"id":"jvu4s6b19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Growth Hormone Receptor Antagonist<\/li><\/ul>"},"3":{"id":"jvu4s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jvu4s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jvu4s7","title":"Mechanism Of Action","mono":"Pegvisomant is a recombinant growth hormone-receptor antagonist which selectively binds to the growth hormone (GH) receptors on the cell surface. By blocking the binding of endogenous GH, pegvisomant causes a decrease in serum concentrations of insulin-like growth hormone (IGF-I), IGF-binding protein -3, and the acid-labile subunit.<br\/>"},"8":{"id":"jvu4s8","title":"Pharmacokinetics","sub":{"0":{"id":"jvu4s8b23","title":"Absorption","mono":"<ul><li>Bioavailability: (subcutaneous), 57% (for a 20-mg subcutaneous dose relative to a 10-mg IV dose)<\/li><li>Tmax: (subcutaneous), 33 to 77 hr<\/li><\/ul>"},"1":{"id":"jvu4s8b24","title":"Distribution","mono":"Vd: (subcutaneous), 7 L <br\/>"},"3":{"id":"jvu4s8b26","title":"Excretion","mono":"<ul><li>Renal: (subcutaneous), less than 1% recovered in urine over 96 hr<\/li><li>Total body: (subcutaneous), 28 to 36 mL\/hr<\/li><\/ul>"},"4":{"id":"jvu4s8b27","title":"Elimination Half Life","mono":"(subcutaneous), 6 days <br\/>"}}},"9":{"id":"jvu4s9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>reconstitute with Sterile Water for Injection, USP; do not shake vial<\/li><li>use only 1 dose per vial<\/li><li>use within 6 hr of reconstitution<\/li><li>administer subcutaneously in the thigh, buttocks, upper arm, or abdomen; rotate injection sites daily<\/li><\/ul>"},"10":{"id":"jvu4s10","title":"Monitoring","mono":"<ul><li>serum insulin-like growth-hormone (IGF-I) levels; at 4-6 weeks after initiating or changing therapy and at least every 6 months after IGF-I levels have normalized<\/li><li>control of acromegaly signs and symptoms<\/li><li>liver function tests (eg, AST, AST, total bilirubin, alkaline phosphatase); at baseline; if levels normal, obtain levels monthly during first 6 months, quarterly for next 6 months, and biannually for the next year; if baseline levels are less than or equal to 3 times upper limit of normal (ULN), obtain levels monthly for at least 1 year and then biannually for the next year; if baseline levels are greater than 3 times ULN, close monitoring required if treatment is initiated<\/li><li>abnormal liver function tests (LFT) during treatment; if levels greater or equal to 3 times the upper limit of normal (ULN) but less than 5 times the ULN, obtain LFTs weekly; if levels at least 5 times ULN or transaminase level at least 3 times ULN with any increase in serum total bilirubin, discontinue therapy and obtain LFTs frequently if therapy is reinitiated<\/li><li>signs or symptoms of liver dysfunction<\/li><li>signs and symptoms of growth-hormone deficiency<\/li><li>diabetic patients: serum glucose and signs and symptoms of hypoglycemia<\/li><li>growth-hormone secreting tumors: imaging scans of the sella turcica periodically<\/li><\/ul>"},"11":{"id":"jvu4s11","title":"How Supplied","mono":"<b>Somavert<\/b><br\/>Subcutaneous Powder for Solution: 10 MG, 15 MG, 20 MG, 25 MG, 30 MG<br\/>"},"13":{"id":"jvu4s13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report a latex sensitivity prior to administration, as vial stopper contains latex.<\/li><li>Drug may cause peripheral edema, pain, infection, flu-like symptoms, nausea, and diarrhea.<\/li><li>Instruct patient to report signs\/symptoms of hepatotoxicity (nausea, fatigue, jaundice, right upper quadrant tenderness).<\/li><li>Patients with diabetes mellitus should monitor for and report changes in glycemic control, as antidiabetic medication dosages may need to be adjusted.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to report use of opioid medicines, as dosage adjustment of pegvisomant may be required.<\/li><\/ul>"}}}